Don Nicholson

BioTech guy. Ex-BigPharma. Father, husband, sailboat racer & guitar aficionado. Tweets are mine.

[NodThera @NodThera]

Today we reached another exciting clinical milestone, announcing positive data from a Phase Ib/IIa #cardiovascular (CV) risk study of lead #NLRP3 #inflammasone inhibitor candidate, NT-0796.

For more: https://t.co/pU187hHJjj

#Neuroinflammation #DrugDiscovery #obesity

[Don Nicholson @DonWNicholson]

@AlexHarding7 Such uninformed speculation, from someone I so highly respect. Read the manuscript, and consider these points as well:

[NodThera @NodThera]

We are pleased to announce that the first patients have been dosed in a Phase Ib/IIa #cardiovascular risk study to assess the impact of NT-0796 on cardio-metabolic biomarkers and #neuroinflammation.

For more: https://t.co/3UXV2JRfAr

#NLRP3

[Jnana Therapeutics @jnanatx]

On Thursday, Joanne Kotz, Ph.D., Co-Founder & CEO, and Doug Pagan, CFO and COO, kick off Jnana’s fall investor conference calendar during a fireside chat at 1:50 p.m. at @Citi’s 18th Annual BioPharma Conference. https://t.co/8Fo26U7nve #drugdiscovery #biotechnology

[Scrip, Citeline Commercial @PharmaScrip]

NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy
https://t.co/VyFI6wVDOv #PharmaScrip

[Nature Biotechnology @NatureBiotech]

Why gene therapies must go virus-free https://t.co/xcQEQmjtlm

[Don Nicholson @DonWNicholson]

Pure CDN talent. Don't miss the flute.

[Don Nicholson @DonWNicholson]

Very cool clinical proof of mechanism: inhibition of SLC6A19-mediated re-uptake of phenylalanine in the kidney. JNT-517 modulates a novel, cryptic allosteric site to do so.

[Jnana Therapeutics @jnanatx]

Today, we reported positive topline results from our Phase 1a clinical study of JNT-517, a potential first-in-class oral treatment for #PKU. JNT-517 demonstrated proof of mechanism and was safe and well tolerated. The Phase 1b is now open for enrollment. https://t.co/sNutjb0hGW

[Joanne Kotz @JoanneKotz]

We are thrilled to be working with fantastic colleagues at Roche to leverage our RAPID platform to advance programs targeting challenging-to-drug targets, including this immune protein-protein interaction.

https://t.co/v5m9z2C0rV

[Don Nicholson @DonWNicholson]

Totally!

[Rich Law @drrichjlaw]

"Drugging the undruggable" is such an annoying nonsense phrase with all sorts of weird consequences for those that believe it's actually a thing!

[Moderna @moderna_tx]

Moderna and @generationbio announced today that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral #genetic medicine platform. The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic #medicines.

Read more: https://t.co/wbu8VZL3UL

[Don Nicholson @DonWNicholson]

Hey fellow vinyl lovers. Great album, especially the A side. ‘Strange Conversation’ a must listen.

[Don Nicholson @DonWNicholson]

Exciting year ahead for @DiscMedicine. Excellent article from @endpts on today's news:
With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital - https://t.co/2arIC5AeEf

[Disc Medicine @DiscMedicine]

We are delighted to announce a $62.5 million financing, led by @BainCapital. This investment adds to our financial strength during an exciting year for Disc as we look towards multiple data readouts and trial initiations across our #hematology portfolio. https://t.co/XCx98OsdP5

[Don Nicholson @DonWNicholson]

@DiscMedicine Bravo team Disc (aka IRON)

[Disc Medicine @DiscMedicine]

Disc is excited to announce a licensing agreement with Mabwell Therapeutics for novel investigational anti-#TMPRSS6 antibodies, including phase 1-ready MWTX-003, which will expand our portfolio of programs to control #iron homeostasis!
Read more here: https://t.co/03znC5mjna

[Disc Medicine @DiscMedicine]

Today we announced Disc has completed its merger with Gemini Therapeutics. The combined company, advancing Disc’s pipeline of hematology programs, will commence trading under the ticker symbol $IRON
Read more: https://t.co/uYfpVggVZ6

[Don Nicholson @DonWNicholson]

Thanks Abbas. @AbbasRKazimi It takes a village...

[Abbas Kazimi @AbbasRKazimi]

So much credit & a big 'thank you' to @DonWNicholson for driving us to go after the JH2/allosteric domain of TYK2 as he always said “TYK2 is the most elegant and genetically validated drug target for I&I diseases" https://t.co/bahDI9Hkpw

[Don Nicholson @DonWNicholson]

👇

[Kymera Therapeutics @KymeraTx]

Today, we shared positive clinical data from our KT-474 Phase 1 hidradenitis suppurativa and atopic dermatitis patient cohort, as well as updates on our three oncology programs, KT-413, KT-333 and KT-253. For more information, please visit: https://t.co/ZM00lr3BJM

[Don Nicholson @DonWNicholson]

Thanks @JebKeiper ! You are a class act.

[Jeb Keiper @JebKeiper]

Congrats to @LifeSciVC as well, who co-founded this company and was first CEO and continues to serve as Chair. Big thanks as well to my mentor @DonWNicholson who proceeded me as CEO and was a staunch supporter of pivoting to the allosteric pocket of TYK2.